For two decades, a promising class of cancer drugs known as CD40 agonist antibodies has been plagued by a paradox: they worked beautifully in animals but caused dangerous, often fatal, side effects in humans. In August 2025, a team at Rockefeller University published results in the journal Cancer Cell showing that a redesigned version of this drug, combined with a change in how it is delivered, has cleared that long-standing hurdle. In a phase 1 trial involving 12 patients with metastatic cancers, six saw their tumors shrink, and two achieved complete remission, a result that has reignited interest in a therapy that was once considered a dead end.
A Two-Decade History of Promise and Pain
To understand why these latest results are generating such cautious excitement, it is necessary to look back at the history of CD40 agonist antibodies. For over 20 years, scientists have explored this group of drugs because early experiments suggested they could strongly activate the immune system to destroy cancer cells. The CD40 protein is a key receptor on immune cells, and stimulating it was thought to be a powerful way to turn the body’s own defenses against tumors. In animal models, these drugs showed great promise, effectively killing cancer cells by engaging the immune system.
However, the translation to human clinical trials was fraught with disappointment. According to Rockefeller University, the drugs had limited impact on patients and caused dangerously systemic inflammatory responses. Even at low doses, patients experienced severe adverse reactions, including low platelet counts and liver toxicity. These side effects were not merely uncomfortable; they were dangerous and often led to the termination of trials. The core problem was that the drugs, when administered systemically through the bloodstream, triggered an immune response that was too broad and too intense, damaging healthy tissue along with the cancer.
This pattern of failure persisted for years, leading many in the field to doubt the viability of targeting CD40. The encouraging part of the current story is that researchers did not abandon the target. Instead, they looked for ways to refine the drug and change the delivery method to bypass the toxicity that had previously stalled progress.
The 2018 Breakthrough in the Lab
The turning point came in 2018, when the lab of Jeffrey V. Ravetch at Rockefeller University reported a potential breakthrough. Ravetch’s team engineered an enhanced CD40 agonist antibody designed to improve efficacy while limiting serious side effects. This was not just a minor tweak; it involved a fundamental redesign of the antibody’s structure. The research relied on genetically engineered mice that mimic key human immune pathways, allowing the team to test the new design in a system that closely approximated human biology.
The findings from this 2018 research suggested that the therapy might work better in people if it were delivered differently. The key shift was moving away from systemic administration, where the drug circulates through the entire body, to a local approach. The redesigned drug, dubbed 2141-V11, was intended to be administered by injecting it directly into tumors rather than into the bloodstream. This change in delivery was critical. By targeting the drug locally, the researchers hoped to activate the immune system at the site of the cancer without triggering the widespread inflammation that had plagued previous trials.
The next step, as outlined in the source material, was to test this modified approach in a clinical trial to see if the drug’s impact on cancer patients could be realized without the severe toxicity seen in the past. The transition from the mouse model to the human trial was the critical bridge that this new study now crosses.
Phase 1 Results: Shrinkage and Remission
The results from the phase 1 clinical trial of 2141-V11 were published in Cancer Cell in August 2025. The study involved 12 patients with metastatic cancers, a group of individuals who typically have limited treatment options. In this small but significant cohort, six patients saw their tumors shrink. More remarkably, two of these patients experienced complete remission, meaning their cancers disappeared entirely.
First author Juan Osorio, a visiting assistant professor in Ravetch’s Leonard Wagner Laboratory of Molecular Genetics and Immunology and a medical oncologist at Memorial Sloan Kettering Cancer Center, described the results as quite remarkable. “Seeing these significant shrinkages and even complete remission in such a small subset of patients is quite remarkable,” Osorio stated. For patients with metastatic disease, complete remission is a rare and highly desirable outcome, and seeing it in half of the patients in this early trial is a strong signal of the drug’s potential.
The trial design was crucial in achieving these results. By injecting the drug directly into the tumor, the team avoided the systemic exposure that previously led to liver damage and low platelet counts. The local delivery allowed the immune system to be activated precisely where it was needed, reducing the risk of off-target effects. This approach has effectively solved the toxicity problem that defined the previous two decades of CD40 agonist research.
The Abscopal Effect and Future Implications
One of the most striking findings from the trial was the “abscopal” effect. Notably, the effect was not limited to the tumors that were directly injected with the drug. Tumors elsewhere in the body either got smaller or were destroyed by immune cells. This phenomenon, where a local treatment triggers a systemic response, is rare in clinical oncology.
Jeffrey V. Ravetch noted that this effect, where you inject locally but see a systemic response, is not something seen very often in any clinical treatment. He described it as another very dramatic and unexpected result from the trial. This suggests that the local injection of 2141-V11 is not just treating the specific tumor it is injected into, but is also training the immune system to recognize and attack cancer cells throughout the body. This systemic immune activation is a key mechanism of action for many successful immunotherapies, but achieving it with a CD40 agonist had previously been elusive due to toxicity.
The success of this specific CD40 agonist has already sparked a number of other clinical trials involving a variety of cancers. The broader immunotherapy landscape is now looking at this approach with renewed interest. While the trial was small, the data provides a clear path forward. The ability to safely activate the immune system against cancer, both locally and systemically, represents a significant advance in the field. For patients, this means that a class of drugs once written off as too dangerous may now offer a viable and effective treatment option. However, as with all early-stage trials, further studies are needed to confirm these results in larger populations. Patients considering immunotherapy should talk to their doctor to discuss the latest research and what it may mean for their specific case. The encouraging part is that the scientific community has found a way to make this powerful tool safe, opening the door for a new era of cancer treatment.
Sources
- The rockefeller university
- Scientists inject one tumor and watch cancer vanish across the body
- Cancer immunotherapy
- Immune Checkpoint Inhibitors Market Size, Share, Trends, and Global Forecast to 2030 | Next-Generation Targets and Combination Therapies Create New Growth Opportunities
Photo: NIH Image Gallery (Public domain)
